Journal of Clinical Research & Bioethics

Ethical Challenges in Modern Clinical Research Practices

Sarah wisely^* Department of Bioethics, University of Melbourne, Melbourne, Australia
^*Correspondence: Sarah wisely, Department of Bioethics, University of Melbourne, Melbourne, Australia, Email:

Received: 01-Jan-2025, Manuscript No. JCRB-25-28949; Editor assigned: 03-Jan-2025, Pre QC No. JCRB-25-28949 (PQ); Reviewed: 17-Jan-2025, QC No. JCRB-25-28949; Revised: 24-Jan-2025, Manuscript No. JCRB-25-28949 (R); Published: 31-Jan-2025, DOI: 10.35248/2155-9627.25.16.509

Description

Ethical challenges in modern clinical research practices continue to evolve alongside rapid advancements in science, technology and globalization [1]. While clinical research is essential for the development of new treatments, drugs and medical technologies, it inherently involves human participation, making ethical considerations not just important, but foundational. These challenges arise at various stages of research, from the initial planning and recruitment of participants to data analysis and publication. Navigating them requires a balance between scientific progress and the protection of human rights and dignity [2].

One of the most prominent ethical issues in clinical research is informed consent [3]. Ensuring that participants understand the purpose, risks, benefits and procedures involved in a study is critical. However, in practice, the consent process often becomes a legal formality rather than a genuine dialogue [4]. The complexity of medical terminology and the pressure to participate, especially for patients with limited treatment options, can impair true understanding. Vulnerable populations, such as those with limited literacy, mental illness, or economic disadvantage, are particularly at risk of being inadequately informed or feeling coerced [5].

Another challenge is the fair selection of research participants. Historically, certain groups, particularly racial minorities, the poor and prisoners, have been disproportionately involved in high-risk studies with little personal benefit. Modern ethics demand that participant selection be equitable and scientifically justified, yet disparities still occur [6]. This is compounded by the globalization of clinical trials, where studies are increasingly conducted in low- and middle-income countries. While this may offer access to populations that are otherwise underrepresented in research, it also raises concerns about exploitation, inadequate regulation and lack of post-trial access to successful treatments [7].

Privacy and confidentiality in clinical research have become more complex in the digital age. The use of electronic health records, genetic data and large datasets in research poses risks to individual privacy, even when data is anonymzed [8]. Technological breaches and insufficient data protection protocols can result in the exposure of sensitive personal information. Ethical research must ensure robust data security measures and maintain transparency about how data is collected, stored and shared.

The role of commercial interests in research is another area fraught with ethical tension. Pharmaceutical companies and other sponsors often fund clinical trials, which can lead to conflicts of interest. Researchers may feel pressured to produce favorable results or withhold negative findings, compromising scientific integrity and public trust. Co-writing, selective reporting and manipulation of data for marketing purposes are all documented issues that undermine the ethical standards of research. The drive for positive outcomes must never override the commitment to reality and patient welfare [9].

Participant compensation also raises ethical questions. While compensating individuals for their time and inconvenience is justifiable, excessive incentives may unduly influence participation, particularly among economically disadvantaged individuals. This can blur the lines between voluntary consent and coercion. Ethical guidelines must carefully consider what constitutes fair compensation without exerting undue influence.

Post-trial responsibilities are increasingly recognized as a critical ethical concern. Participants who contribute to the development of new treatments often do not have access to the resulting therapies once the study concludes. This is especially problematic in international trials, where participants in resource-poor settings help develop treatments that become unaffordable or unavailable in their own countries [10].

References

1. Juárez M, Lam S, Bohrer BM, Dugan ME, Vahmani P, Aalhus J, et al. Enhancing the nutritional value of red meat through genetic and feeding strategies. Foods. 2021;10(4):872.

   [Crossref] [Google Scholar] [PubMed]

2. Kahn-Krell A, Pretorius D, Ou J, Fast VG, Litovsky S, Berry J, et al. Bioreactor suspension culture: Differentiation and production of cardiomyocyte spheroids from human induced pluripotent stem cells. Front Bioeng Biotechnol. 2021;9:674260.

   [Crossref] [Google Scholar] [PubMed]

3. Torizal FG, Utami T, Lau QY, Inamura K, Nishikawa M, Sakai Y. Dialysis based-culture medium conditioning improved the generation of human induced pluripotent stem cell derived-liver organoid in a high cell density. Sci Rep. 2022;12(1):20774.

   [Crossref] [Google Scholar] [PubMed]

4. Lin H, Du Q, Li Q, Wang O, Wang Z, Sahu N, et al. A scalable and efficient bioprocess for manufacturing human pluripotent stem cell-derived endothelial cells. Stem Cell Reports. 2018;11(2):454-469.

   [Crossref] [Google Scholar] [PubMed]

5. Yan L, Jiang B, Li E, Wang X, Ling Q, Zheng D, et al. Scalable generation of mesenchymal stem cells from human embryonic stem cells in 3D. Int J Biol Sci. 2018;14(10):1196-1210.

   [Crossref] [Google Scholar] [PubMed]

6. Sexton AE, Garnett T, Lorimer J. Framing the future of food: The contested promises of alternative proteins. Environ Plan E Nat Space. 2019;2(1):47-72.

   [Crossref] [Google Scholar] [PubMed]

7. Kumar M, Tomar M, Potkule J, Punia S, Dhakane-Lad J, Singh S, et al. Functional characterization of plant-based protein to determine its quality for food applications. Food Hydrocoll. 2022;123:106986.

   [Crossref] [Google Scholar]

8. Yao Y, Yuen Jr JS, Sylvia R, Fennelly C, Cera L, Zhang KL, et al. Cultivated meat from aligned muscle layers and adipose layers formed from glutenin films. ACS Biomater Sci Eng. 2024;10(2):814-824.

   [Crossref] [Google Scholar] [PubMed]

9. Ben-Arye T, Shandalov Y, Ben-Shaul S, Landau S, Zagury Y, Ianovici I, et al. Textured soy protein scaffolds enable the generation of three-dimensional bovine skeletal muscle tissue for cell-based meat. Nat Food. 2020;1(4):210-220.

   [Crossref] [Google Scholar]

10. Xiang N, Yao Y, Yuen Jr JS, Stout AJ, Fennelly C, Sylvia R, et al. Edible films for cultivated meat production. Biomaterials. 2022;287:121659.

    [Crossref] [Google Scholar] [PubMed]